Your browser doesn't support javascript.
loading
Successful Treatment of Primary Mediastinal Large B-cell Lymphoma with DA-EPOCH-Rituximab Therapy in a Transgender Woman.
Nakao, Sanshiro; Tanaka, Sho; Abe, Kazuki; Komiyama, Tomomi; Sugiura, Yoshiya; Nakaseko, Chiaki; Shimizu, Naomi.
Afiliação
  • Nakao S; Department of Hematology, Toho University Sakura Medical Center, Japan.
  • Tanaka S; Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan.
  • Abe K; Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan.
  • Komiyama T; Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan.
  • Sugiura Y; Department of Surgical Pathology, Toho University Sakura Medical Center, Japan.
  • Nakaseko C; Department of Hematology, International University of Health and Welfare School of Medicine, Japan.
  • Shimizu N; Department of Hematology, Toho University Sakura Medical Center, Japan.
Intern Med ; 2023 Nov 20.
Article em En | MEDLINE | ID: mdl-37981304
ABSTRACT
In recent years, lesbian, gay, bisexual, and transgender (LGBT) populations have been gaining acceptance in society. However, very few cases of malignancy in the LGBT population have been reported thus far. We herein report a transgender woman receiving estrogen supplementation who developed primary mediastinal large B-cell lymphoma (PMBCL) and was treated with dose-adjusted EPOCH-rituximab (DA-EPOCH-R) therapy. The patient achieved complete remission after the sixth course of DA-EPOCH-R therapy. To help this LGBT patient continue receiving chemotherapy smoothly on admission, adjusting the hospital environment, such as the allocation of rooms, was essential.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article